Synonyms: Accolate® | ICI-204219
zafirlukast is an approved drug (FDA (1996))
Compound class:
Synthetic organic
Comment: Zafirlukast is an oral leukotriene receptor antagonist (LTRA), with selectivity for cysteinyl leukotriene receptor 1 (CysLT1 receptor).
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖View more information in the IUPHAR Pharmacology Education Project: zafirlukast |
|
No information available. |
Summary of Clinical Use |
Used in the prophylaxis and chronic treatment of asthma. |
Mechanism Of Action and Pharmacodynamic Effects |
Antagonist of the leukotriene receptor CYSLTR1. This action clears the breathing passages by reducing airway constriction and inflammation and reduces build-up of mucus in the lungs.. |
External links |
For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com |